Market Applicability

 
News Articles for Market Applicability top ^
2014/12/1
The German Federal Institute for Drugs and Medical Devices ("BfArM") has validated the European Marketing Authorization Application submitted for RIZAPORT™ and initiated its formal review of the application on November 25, 2014 IntelGenx and RedHill continue to work with the FDA to resolve the remaining Chemistry, Manufacturing and Controls ("CMC") issues and secure a compliant source of the raw material, in order to advance potential FDA approval of the U.S. New Drug Application submitted by the companies RIZAPORT™ oral thin film formulation of rizatriptan for acute migraines presents an attractive therapeutic alternative for many migraine patients, including those suffering from migraine-related nausea, due to its convenient dosing, lack of need for water intake and pleasant flavoring  SAINT LAURENT, Quebec, Dec.
Sign-up for IntelGenx and RedHill Biopharma Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines investment picks
2014/12/1
The German Federal Institute for Drugs and Medical Devices (BfArM) has validated the European Marketing Authorization Application submitted for RIZAPORT ™ (RHB-103) and initiated its formal review of the application on November 25, 2014 RedHill and IntelGenx continue to work with the FDA to resolve the remaining Chemistry, Manufacturing and Controls (CMC) issues and secure a compliant source of the raw material, in order to advance potential FDA approval of the U.S. New Drug Application submitted by the companies RIZAPORT ™ oral thin film formulation of rizatriptan for acute migraines presents a potentially attractive therapeutic alternative for many migraine patients, including those suffering from migraine-related nausea, due to its convenient dosing, lack of need for water intake and pleasant flavoring TEL-AVIV, Israel, Dec.
Sign-up for RedHill Biopharma and IntelGenx Announce Acceptance for Review of European Marketing Application for RIZAPORT(TM) for Migraines investment picks
2014/12/31
The UK MHRA has validated the European marketing application for the indications of chemotherapy and radiotherapy-induced nausea and vomiting; MHRA's feedback is expected during H2/2015 BEKINDA ™ (RHB-102) is a proprietary once-daily oral pill formulation of the antiemetic drug ondansetron, targeting a worldwide potential market with estimated annual sales of $940 million BEKINDA ™ is also being developed for acute gastroenteritis and gastritis, with an ongoing Phase III study in the U.S. and top-line data expected during H2/2015 TEL-AVIV, Israel, Dec.
Sign-up for RedHill Biopharma Announces Acceptance for Review of BEKINDA(TM) European Marketing Application for Oncology Support investment picks
2015/1/8
Virtusa Corporation (NASDAQ GS: VRTU), a global business consulting and IT outsourcing company that combines innovation, technology leadership and industry solutions to transform the customer experience, today announced it has recently been named an Emerging Player in large capital markets application outsourcing relationships by Everest Group, an advisory and research firm on global services.
Sign-up for Everest Group Names Virtusa Emerging Player in PEAK Matrix™ for Large Capital Markets Application Outsourcing Relationships investment picks
2014/12/11
Successful Pre-Submission Meeting with European Medicines Agency Completed CRANBURY, N.J., Dec.
Sign-up for Amicus Therapeutics to Submit European Marketing Application for Migalastat Monotherapy for Fabry Disease investment picks

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Market Applicability
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Market Access  |  Next: Market Approval